RxSight, Inc. (NASDAQ:RXST) Insider Ilya Goldshleger Sells 3,100 Shares

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of RxSight stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $50.64, for a total value of $156,984.00. Following the transaction, the insider now directly owns 42,246 shares in the company, valued at approximately $2,139,337.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.79, for a total transaction of $154,349.00.
• On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.68, for a total transaction of $154,008.00.
• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total transaction of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.78, for a total transaction of $154,318.00.
• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.19, for a total value of $155,589.00.
• On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total value of $155,279.00.
• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $48.26, for a total value of $149,606.00.
• On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.01, for a total transaction of $148,831.00.
• On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.02, for a total transaction of $151,962.00.
• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $49.29, for a total transaction of $153,045.45.

RxSight Trading Down 0.3 %

Shares of NASDAQ RXST traded down $0.13 during trading hours on Monday, hitting $50.25. 324,504 shares of the company traded hands, compared to its average volume of 468,027. The company’s 50 day moving average price is $51.91 and its 200 day moving average price is $53.67. RxSight, Inc. has a 12 month low of $20.66 and a 12 month high of $66.54. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of -49.26 and a beta of 1.20.

RxSight (NASDAQ:RXST) last announced its earnings results on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.06. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The business had revenue of $34.89 million for the quarter, compared to the consensus estimate of $32.33 million. During the same quarter in the prior year, the firm posted ($0.40) earnings per share. The business’s revenue for the quarter was up 67.6% on a year-over-year basis. Equities analysts anticipate that RxSight, Inc. will post -0.81 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on RXST. Wells Fargo & Company dropped their price objective on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Stifel Nicolaus dropped their price target on RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Oppenheimer reduced their price objective on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and set a $66.00 target price on shares of RxSight in a research report on Friday, September 13th. Finally, BTIG Research boosted their price target on shares of RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $60.14.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of RXST. CWM LLC boosted its stake in shares of RxSight by 727.5% during the second quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after purchasing an additional 371 shares during the period. Nisa Investment Advisors LLC increased its stake in RxSight by 854.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after buying an additional 521 shares during the period. Quest Partners LLC bought a new stake in RxSight during the 2nd quarter valued at about $41,000. Larson Financial Group LLC purchased a new stake in RxSight in the 1st quarter valued at about $51,000. Finally, Amalgamated Bank grew its stake in RxSight by 21.3% in the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after acquiring an additional 207 shares in the last quarter. Hedge funds and other institutional investors own 78.78% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.